129 related articles for article (PubMed ID: 23346558)
1. European Medicines Agency guidelines to increase the pace of biosimilar development.
Parks L
Bioanalysis; 2012 Nov; 4(22):2665. PubMed ID: 23346558
[No Abstract] [Full Text] [Related]
2. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
3. Effective pharmaceutical regulation needs alignment with doctors.
Ebbers HC; Pieters T; Leufkens HG; Schellekens H
Drug Discov Today; 2012 Feb; 17(3-4):100-3. PubMed ID: 22001600
[TBL] [Abstract][Full Text] [Related]
4. Clinical development and trial design of biosimilar products: a Japanese perspective.
Nagasaki M; Ando Y
J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
[TBL] [Abstract][Full Text] [Related]
5. The biosimilar insulin landscape: current developments.
Lavalle-González FJ; Khatami H
Postgrad Med; 2014 Oct; 126(6):81-92. PubMed ID: 25414937
[TBL] [Abstract][Full Text] [Related]
6. The regulatory framework of biosimilars in the European Union.
Minghetti P; Rocco P; Cilurzo F; Vecchio LD; Locatelli F
Drug Discov Today; 2012 Jan; 17(1-2):63-70. PubMed ID: 21856438
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar competition: lessons from Europe.
Grabowski H; Guha R; Salgado M
Nat Rev Drug Discov; 2014 Feb; 13(2):99-100. PubMed ID: 24445562
[No Abstract] [Full Text] [Related]
8. Position paper from the Spanish Society of Rheumatology on biosimilar drugs.
Abad Hernández MÁ; Andreu JL; Caracuel Ruiz MÁ; Belmonte Serrano MÁ; Díaz-González F; Moreno Muelas JV
Reumatol Clin; 2015; 11(5):269-78. PubMed ID: 25982595
[TBL] [Abstract][Full Text] [Related]
9. Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries.
Gulácsi L
Eur J Health Econ; 2014 May; 15 Suppl 1():S1-4. PubMed ID: 24832830
[No Abstract] [Full Text] [Related]
10. The European biosimilars market remains underdeveloped.
Prescrire Int; 2015 Mar; 24(158):82. PubMed ID: 25897465
[No Abstract] [Full Text] [Related]
11. [Biological and biosimilar drugs: Clarifying concepts].
Rodriguez Cumplido D; Asensio Ostos C
Aten Primaria; 2018; 50(6):323-324. PubMed ID: 29605234
[No Abstract] [Full Text] [Related]
12. Biosimilars in rheumatology: perspective and concerns.
Scheinberg MA; Azevedo VF
Rheumatology (Oxford); 2014 Mar; 53(3):389-90. PubMed ID: 23878310
[No Abstract] [Full Text] [Related]
13. The 9
Chu L
Drugs Today (Barc); 2018 Jul; 54(7):445-449. PubMed ID: 30090881
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar drugs, myths and reality.
Hernández-García C
Reumatol Clin; 2014; 10(6):351-2. PubMed ID: 25037069
[No Abstract] [Full Text] [Related]
15. The advent of biosimilars: challenges and risks.
Müller R; Renner C; Gabay C; Cassata G; Lohri A; Hasler P
Swiss Med Wkly; 2014; 144():w13980. PubMed ID: 24984255
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar insulins.
Heinemann L
Expert Opin Biol Ther; 2012 Aug; 12(8):1009-16. PubMed ID: 22583127
[TBL] [Abstract][Full Text] [Related]
17. European Medicines Agency support mechanisms fostering orphan drug development.
Butlen-Ducuing F; Rivière F; Aarum S; Llinares-Garcia J
Drug News Perspect; 2010; 23(1):71-81. PubMed ID: 20155221
[TBL] [Abstract][Full Text] [Related]
18. Preface: issues in biosimilar drug development.
Yao B; Chi E
J Biopharm Stat; 2014; 24(6):1137. PubMed ID: 25360866
[No Abstract] [Full Text] [Related]
19. [What is exactly alike? High-performance analytics for development of biosimilars].
Blüggel M
Pharm Unserer Zeit; 2012 Nov; 41(6):468-73. PubMed ID: 23362550
[No Abstract] [Full Text] [Related]
20. European perspective on biosimilars.
Wadhwa M; Thorpe R
Bioanalysis; 2013 Mar; 5(5):521-4. PubMed ID: 23425266
[No Abstract] [Full Text] [Related]
[Next] [New Search]
